Form 4: Milestone Pharma CFO Granted Equity Awards

Milestone Pharmaceuticals Inc.'s CFO and EVP of Corporate Development, Amit Hasija, was granted 204,000 employee stock options and 136,000 restricted stock units.

Summary

• Amit Hasija, CFO & EVP of Corporate Development at Milestone Pharmaceuticals Inc. (MIST), received equity awards on February 2, 2026.
• The awards include 204,000 employee stock options with an exercise price of $1.97 per share.
• The stock options begin vesting one-fourth (1/4th) on February 2, 2027, with the remaining shares vesting one thirty-sixth (1/36th) each month thereafter, contingent on continued service.
• The stock options have an expiration date of February 2, 2036.
• Additionally, 136,000 Restricted Stock Units (RSUs) were granted, where each RSU represents a contingent right to receive one common share.
• The RSUs vest in four equal annual installments of one-fourth (1/4th) on February 2, 2027, February 2, 2028, February 2, 2029, and February 2, 2030, subject to continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents routine executive compensation designed to align interests and retain talent, rather than indicating a significant operational or financial development.

Positives

• The grant of equity awards to a key executive like the CFO aligns management's interests with those of shareholders, incentivizing long-term performance and retention.
• The vesting schedules encourage the executive to remain with the company for several years, providing stability in leadership.

Future Outlook

The equity awards are structured with multi-year vesting schedules, indicating an expectation of continued service from the CFO and a long-term incentive for performance. The vesting is contingent on the reporting person continuing to provide service through each vesting date.

Industry Context

StockSavvy.ai notes that the granting of stock options and restricted stock units to key executives is a standard practice across the biotechnology and pharmaceutical industries. This compensation structure is designed to attract, retain, and motivate top talent by aligning their financial interests with the long-term success and share price performance of the company.

Stakeholder Impact

• Shareholders: The equity grants aim to align the CFO's interests with shareholder value creation over the long term.
• Employees: The grants may signal stability in executive leadership, potentially boosting morale.

Next Steps

• Amit Hasija's continued service to Milestone Pharmaceuticals Inc. is required for the vesting of the granted stock options and restricted stock units.

Key Dates

Keywords

Milestone Pharmaceuticals, MIST, Amit Hasija, CFO, EVP Corporate Development, Employee Stock Option, Restricted Stock Unit, RSU, Equity Award, Insider Transaction, Form 4, Executive Compensation